Literature DB >> 28318298

Factors Associated with Compliance to Increased Fluid Intake and Urine Volume Following Dietary Counseling in First-Time Kidney Stone Patients.

Aziz Khambati1, Richard S Matulewicz1, Kent T Perry1, Robert B Nadler1.   

Abstract

OBJECTIVE: Increasing fluid intake to achieve a urine volume (UV) of >2.5 L/day decreases stone events. We assessed compliance rates and demographic and clinical variables associated with increased fluid intake and UV in patients with urolithiasis following dietary counseling.
MATERIALS AND METHODS: In a retrospective study, patients with a low baseline UV (<2.5 L/day) on an initial 24-hour urine collection during metabolic stone evaluation were identified between 2010 and 2015. Patients received detailed standardized dietary counseling, including increasing fluid intake to >3 L/day and titrating it to achieve UV >2.5 L/day. A follow-up 24-hour urine collection was performed at 6 months (FU1) and 18 months (FU2) to assess compliance (UV >2.5 L/day) and predictors associated with it.
RESULTS: Our cohort contained 363 patients, 53.4% men and 46.6% women. The mean UV of baseline, FU1, and FU2 urine collections was 1.63, 2.52, and 2.48 L, respectively. The compliance rate of obtaining UV of >2.5 L was 50.1% at 6 months. On logistic regression, male sex (odds ratio [OR] 3.27, 95% confidence interval [CI] 1.94, 5.52, p < 0.001), urolithiasis-related procedures such as ureteroscopy (OR 2.31, 95% CI 1.20, 4.42, p = 0.01) or percutaneous nephrolithotomy (OR 3.48, 95% CI 1.58, 7.63, p = 0.002), and baseline 24-hour UV >1 L (OR 3.00, 95% CI 1.02, 8.76, p = 0.04) were associated with greater odds of compliance. Age >58 years (OR 0.39, 95% CI 0.20, 0.75, p = 0.005) and presence of lower urinary tract symptoms (OR 0.50, 95% CI 0.26, 0.95, p = 0.03) were associated with lower odds of compliance. Ethnicity, body mass index, renal function, marital status, renal stone burden, stone type, and household income were not associated with compliance.
CONCLUSIONS: In stone formers, compliance to fluid intake recommendations as measured by 24-hour UV is roughly 50%. Understanding risk factors for noncompliance, especially in at risk patients, can be used for quality improvement initiatives and reducing stone events.

Entities:  

Keywords:  compliance; fluid intake; metabolic stone evaluation; urolithiasis

Mesh:

Year:  2017        PMID: 28318298     DOI: 10.1089/end.2016.0836

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  6 in total

Review 1.  The role of fluid intake in the prevention of kidney stone disease: A systematic review over the last two decades.

Authors:  Kithmini Nadeeshani Gamage; Enakshee Jamnadass; Sadaf Karim Sulaiman; Amelia Pietropaolo; Omar Aboumarzouk; Bhaskar K Somani
Journal:  Turk J Urol       Date:  2020-06-05

2.  Acceptability of Mobile Health Technology for Promoting Fluid Consumption in Patients With Nephrolithiasis.

Authors:  Necole M Streeper; Kathleen Lehman; David E Conroy
Journal:  Urology       Date:  2018-08-29       Impact factor: 2.649

3.  Just-in-time adaptive intervention to promote fluid consumption in patients with kidney stones.

Authors:  David E Conroy; Ashley B West; Deborah Brunke-Reese; Edison Thomaz; Necole M Streeper
Journal:  Health Psychol       Date:  2020-12       Impact factor: 4.267

4.  Temporal Trends of Dietary Risk Factors after a Diagnosis of Kidney Stones.

Authors:  Pietro Manuel Ferraro; Tamara Da Silva Cunha; Eric N Taylor; Gary C Curhan
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-19       Impact factor: 10.614

5.  Predictive Factors for Achieving the Recommended AUA Daily Urine Production in Patients With Nephrolithiasis.

Authors:  Kimberly Tay; Anojan Navaratnam; Sean McAdams; Mira Keddis; Matthew Neville; Mitchell R Humphreys
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-05-27

6.  The relationship between kidney stones and dietary habits.

Authors:  Akeel T Al-Kazwini; Maan S Al-Arif; Suhad S Abu-Mweis; Tarek F Al-Hammouri
Journal:  Res Rep Urol       Date:  2019-07-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.